Sort:
Open Access Research Article Just Accepted
Neutrophil-excluding nanoparticles abrogate biomechanical and immunological barriers to sensitize radioimmunotherapy
Nano Research
Available online: 26 October 2026
Abstract PDF (20.7 MB) Collect
Downloads:10

Desmoplastic tumors are highly resistant to treatment, largely due to their dense fibrotic stroma. Paradoxically, radiotherapy (RT) exacerbates this challenge by triggering a pro-fibrotic and immunosuppressive cascade. Here, we identify an RT-induced neutrophil-fibroblast-macrophage hierarchy as a key driver of this therapeutic resistance. To circumvent this barrier, we developed a nano-modulator, termed NanoNex, to precisely intervene in this cellular crosstalk. By transcriptionally inhibiting post-RT neutrophil recruitment via SMAD3 suppression, NanoNex effectively abrogates neutrophil-dependent stromal deposition and alleviates biomechanical tension. Crucially, this remodeling of the tumor microenvironment restores macrophage plasticity and unlocks their responsiveness to immune adjuvants, enabling potent M1 polarization. In refractory murine models of pancreatic and breast cancer, NanoNex markedly potentiated radioimmunotherapy, eliciting robust tumor regression. Furthermore, NanoNex induced systemic anti-tumor immune memory in the pancreatic cancer model. Collectively, our findings demonstrate that this nano-enabled neutrophil exclusion strategy serves as a transformative platform to normalize the biomechanical and immunosuppressive tumor microenvironment, converting RT-induced stromal barriers into a permissive landscape for effective radioimmunotherapy.

Research Article Issue
Efficient and targeted drug/siRNA co-delivery mediated by reversibly crosslinked polymersomes toward anti-inflammatory treatment of ulcerative colitis (UC)
Nano Research 2019, 12(3): 659-667
Published: 09 January 2019
Abstract PDF (2.7 MB) Collect
Downloads:129

Co-delivery of anti-inflammatory siRNA and hydrophilic drug provides a promising approach for the treatment of ulcerative colitis (UC). However, lack of a suitable and efficient co-delivery carrier poses critical challenge against their utilization. We herein developed macrophage-targeting, reversibly crosslinked polymersomes (TKPR-RCP) based on the TKPR-modified, poly(ethylene glycol)-b-poly(trimethylene carbonate-co-dithiolane trimethylene carbonate)-b-polyethylenimine (PEG-P(TMC-DTC)-PEI) triblock copolymer, which could efficiently encapsulate TNF-α siRNA and dexamethasone sodium phosphate (DSP) in their hydrophilic core. The cationic PEI segments provided additional electrostatic interactions with cargo molecules to promote the encapsulation, and disulfide crosslinking of the polymersome membrane endowed the TKPR-RCP with high colloidal stability. Because the cationic PEI was embedded in the hydrophilic core, the polymersomes displayed neutral surface charge and thus possessed high serum stability. The TKPR-RCP co-encapsulating TNF-α siRNA and DSP could be efficiently internalized by macrophages (~ 98%) and undergo redox-responsive membrane de-crosslinking to accelerate cargo release in the cytoplasm, thus inducing efficient gene silencing and anti-inflammatory effect. Intravenous injection of the co-delivery TKPR-RCP mediated potent and cooperative anti-inflammatory effect in inflamed colons of UC mice, and significantly prevented animals from colonic injury. This study therefore provides a promising approach for the co-delivery of hydrophilic drug/siRNA toward the treatment of inflammatory bowel diseases.

Total 2